Mina, Michael
▶ Watch on YouTubeCore ideas
Mina's central argument is that cheap, paper-strip rapid antigen tests — not PCR, not lockdowns, and not (yet) vaccines — were the obvious, already-available engineering solution to controlling COVID-19 transmission, and that the US failed to deploy them at scale for regulatory rather than technical or economic reasons. He walks through the underlying virology: rapid antigen tests detect viral proteins and correlate well with actual contagiousness, whereas PCR's extreme sensitivity to viral RNA means it keeps returning positives for weeks after a person is no longer infectious (he likens this to finding DNA at an old crime scene). Because public health's goal is to stop forward transmission, not to reconstruct someone's infection history, he argues antigen tests are the more appropriate public health tool even though they score worse on diagnostic-sensitivity benchmarks against PCR. He frames the policy failure as structural: the FDA only has a regulatory pathway to evaluate tests as medical devices for individual diagnosis, not as public health tools for population-level screening, and no agency (FDA, CDC, or CMS) claims ownership of authorizing a "public health tool" category — leaving cheap tests stuck in regulatory limbo while a medical-device certification path pushes manufacturers toward selling far fewer tests at inflated insurance-billed prices (e.g., $30–100) instead of flooding the market with $1–3 tests. He does a live demonstration of several rapid-test products (Abbott BinaxNOW, a Detect RNA device, an Ellume Bluetooth-connected test) to illustrate the manufacturing simplicity and cost floor, and models the epidemiological math showing that removing even 30-40% of onward transmission (getting the reproduction number below 1) converts exponential growth into exponential decay — meaning the tests don't need to be perfect to break the pandemic's momentum, just Widely and frequently used (his target: 20-40 million tests/day in the US).
Beyond testing, Mina describes a longer-term research program he calls "public health engineering" (he wants MIT to formalize the field): a "global immunological observatory" that profiles blood/saliva samples at scale for antibody responses to hundreds of pathogens simultaneously, aiming to build a real-time "weather map" for infectious disease that could have flagged the novel coronavirus's spread in New York City based on anomalous immune-response patterns months before the first PCR test confirmed it. He discusses a related, more speculative finding from his lab: that a person's overall immunological "fingerprint" (the idiosyncratic combination of antibodies built up against every pathogen they've encountered) is stable and unique enough, even between identical twins, to re-link two anonymous blood samples to the same individual without ever learning their identity — which he presents as a way to gain population-scale epidemiological data while preserving anonymity, while acknowledging it will draw privacy scrutiny. He also discusses future pandemic risk (arguing influenza's segmented, recombination-prone genome makes it a bigger long-term threat than coronaviruses, and that engineered/gain-of-function pathogens now rank among his top civilizational concerns alongside natural pandemics), and reflects at length on his own path — an engineering and physics background, a period as a Buddhist monk in Sri Lanka that ended when the 2004 tsunami hit, then medicine and immunology — framing his effectiveness as coming from combining disciplines rather than mastering one, and his standing advice to young people as: default to seeing solutions rather than only obstacles, since most professional and institutional pushback he's encountered (getting Brigham and the Broad Institute to build COVID testing capacity early in 2020) came from people trained to enumerate reasons something is impossible.
Excerpts
On why rapid antigen tests don't need to be perfect to stop exponential spread:
“This doesn't need to be perfect, we don't have to go from 100 to zero, we just have to go and have those hundred people infect 90 and those 90 people infect you know 82, whatever it might be, and you do that for a few weeks and boom, you have now gone instead of 100 to 500 you've gone from 100 to 20. It's not very hard, and so the way to do that is to let people know that they're infectious.”
On why PCR positivity and contagiousness diverge, and how that distorts test evaluation:
“You might only be infectious for five days but then you'll remain PCR positive for three or four or five weeks. And so when you go and just evaluate these tests and you say, okay, this person's PCR positive, does the rapid antigen test detect that? More often than not it's no, but that's because those people don't need isolation, they're post-infectious... on the FDA's rubric they'll say no, that's only 50 percent sensitive.”
On the regulatory dead zone that kept cheap tests off the market:
“There's this weird definition that any test that gives a result back to an individual is defined by CMS as a medical device requiring medical authorization. But then you go and ask Seema Verma, the head of CMS, okay can these be authorized as public health tools... and Seema Verma says, oh well, we don't have any jurisdiction over point-of-care devices, we only have jurisdiction over lab devices. So nobody has ownership over it, which means they just stay in this purgatory of not being approved.”